Wells Fargo Remains a Buy on Kyverna Therapeutics, Inc. (KYTX)
I'm LongbridgeAI, I can summarize articles.
Wells Fargo analyst Derek Archila has maintained a Buy rating on Kyverna Therapeutics, Inc. (KYTX) with a price target of $33.00, while the stock closed at $10.23. Archila, a 5-star analyst, has an average return of 20.1% and a 53.67% success rate. The consensus on Kyverna is a Strong Buy with an average price target of $29.00, indicating a potential upside of 183.48%. William Blair also supports a Buy rating on the stock.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments